Hormonal
Postmarketing reports of neoplasms are higher for GLP-1 RAs compared to non-GLP-1 agents, but remain rare relative to overall exposure.
While postmarketing reports of neoplasms are higher for GLP-1 RAs, they are still rare. The benefits of weight loss and mortality reduction likely outweigh this small risk for most patients.
Postmarketing reports of neoplasms were 0.9% for non-GLP agents, 5.4% for WM GLP-1 RAs, 4.1% for T2D GLP-1 RAs and 0.7% for GLP-1/GIP RAs.
Why this rating
Based on FAERS data, which is subject to reporting bias and confounding by indication.
Source
Exposure‐adjusted safety and efficacy of GLP‐I and GLP‐1/GIP receptor agonists compared with non‐GLP‐I for weight management and type 2 diabetes: Based on FDA medical and statistical reports of 34 280 safety and 36 312 efficacy subjects
Aishwarya Prasad et al. · British Journal of Clinical Pharmacology · 2026
DOI 10.1002/bcp.70515
More from this paper
- GLP-1/GIP dual receptor agonists (e.g., tirzepatide) produce significantly greater weight loss than GLP-1 receptor agonists (e.g., semaglutide, liraglutide) and non-GLP-1 agents (e.g., orlistat, phentermine/topiramate) in weight management trials.Good
- GLP-1 and GLP-1/GIP receptor agonists are associated with lower exposure-adjusted mortality rates compared to non-GLP-1 weight management agents.Moderate
Related findings · Hormonal
- Initial treatment for type 2 diabetes should be a combination of metformin and either an SGLT-2 inhibitor or a GLP-1 receptor agonist to achieve cardiorenal protection, rather than monotherapy or older agents like sulfonylureas.Strong
- For patients with specific monogenic obesity syndromes (leptin deficiency, POMC/PCSK1/LEPR mutations), targeted pharmacotherapy (recombinant leptin or setmelanotide) is highly effective and should be prioritized, unlike in polygenic obesity.Strong
- Continued weekly administration of 2.4 mg subcutaneous semaglutide prevents weight regain and promotes further weight loss in adults with overweight or obesity, whereas switching to placebo results in significant weight regain.Strong
This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →